CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious ...
We've been pushing the state of the art on how you do AI and machine learning on high-velocity data,' FogHorn CEO David King tells CRN about the startup's edge intelligence capabilities.
Foghorn Therapeutics (FHTX), a clinical-stage biotech company with its sights set on revolutionizing oncology, surprised with top-and-bottom-line beats for Q3. The company is making significant ...
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback